The partners at SR One, a storied corporate biotech VC with investments across a wide range of drug developers on both sides of the Atlantic, are engaged in talks to split away from the pharma giant GlaxoSmithKline, according to sources familiar with a move that’s been in the works since at least late last year.
{iframe}https://endpts.com/scoop-gsks-venture-team-at-sr-one-in-talks-to-spin-off-from-its-big-pharma-founder-now-under-new-rd-management/{/iframe}